

# GD2

## Ganglioside G2.

GD2 is a disialoganglioside expressed on tumors of neuroectodermal origin, including human [neuroblastoma](#) and melanoma, with highly restricted expression on normal tissues, principally to the cerebellum and peripheral nerves in humans.

The relatively tumor specific expression of GD2 makes it a suitable target for immunotherapy with monoclonal antibodies or with artificial T cell receptors.

An example of such antibodies is hu14.18K322A, a monoclonal antibody. This anti-GD2 antibody is currently undergoing a phase II clinical trial in the treatment of previously untreated high risk neuroblastoma given alongside combination chemotherapy prior to stem cell transplant and radiation therapy.

A prior phase I clinical trial for patients with refractory or recurrent neuroblastoma designed to decrease toxicity found safe dosage amounts and determined that common toxicities, particularly pain, could be well managed.

## GD2-CAR T cell therapy

### [GD2-CAR T cell therapy](#)

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=gd2>

Last update: **2024/06/07 02:53**

